NASDAQ:CYTK
Cytokinetics Stock News
$70.11
-1.30 (-1.82%)
At Close: Mar 28, 2024
2 Biotechs That Could Get Bought Out in 2024
06:45am, Wednesday, 03'rd Jan 2024
With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. These two biotechs have repeatedly been rumore
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:00pm, Tuesday, 02'nd Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pre
Cytokinetics CEO on shares soaring, heart drug Aficamten and American heart health
02:19pm, Thursday, 28'th Dec 2023
Robert Blum, Cytokinetics CEO, joins 'The Exchange' to discuss the biotech sector, the company's shares soaring on the latest trial of its heart drug, and more.
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
11:17am, Thursday, 28'th Dec 2023
Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug
04:05pm, Wednesday, 27'th Dec 2023
Shares of Cytokinetics (CYTK) blasted off Wednesday after the firm announced positive results in a study of its experimental heart treatment.
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
01:59pm, Wednesday, 27'th Dec 2023
Demonstrating the positive side of the occasional feast-or-famine nature of publicly traded biotechnology firms, Cytokinetics (NASDAQ: CYTK ) soared Wednesday following the disclosure of its positive
Cytokinetics stock rockets toward a 19-year high after positive trial data on heart disease treatment
07:48am, Wednesday, 27'th Dec 2023
Shares of Cytokinetics Inc. CYTK, +2.49% rocketed 41.1% toward a record one-day gain in premarket trading, after the cardiovascular biopharmaceutical company announced positive results from a Phase 3
Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript
12:29am, Friday, 03'rd Nov 2023
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
06:47pm, Thursday, 02'nd Nov 2023
Cytokinetics (CYTK) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.28 per share a year ago.
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Wednesday, 01'st Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferen
Cytokinetics exploring options after receiving takeover interest - Bloomberg News
02:26pm, Tuesday, 31'st Oct 2023
Heart diseases-focused drug developer Cytokinetics is weighing options after receiving takeover interest, Bloomberg News reported on Tuesday, citing people familiar with the matter.
Cytokinetics to Announce Third Quarter Results on November 2, 2023
04:00pm, Monday, 23'rd Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 2, 2023 at 4:0
Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock?
09:01am, Monday, 09'th Oct 2023
Cytokinetics (CYTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increas
The 3 Best Mid-Cap Stocks to Buy Now: September 2023
04:29pm, Thursday, 07'th Sep 2023
Banking on the Goldilocks narrative, targeting the best mid-cap stocks centers mostly on balance. If you go the small-capitalization route, you'll benefit from maximum upside potential.
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Thursday, 07'th Sep 2023
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere